The Prague Post - Pfizer sees Covid-19 drug sales topping $50 bn in 2022

EUR -
AED 4.251875
AFN 79.977349
ALL 97.574407
AMD 444.555592
ANG 2.071771
AOA 1061.526715
ARS 1460.31657
AUD 1.792111
AWG 2.083695
AZN 1.967471
BAM 1.954269
BBD 2.337469
BDT 140.539906
BGN 1.953881
BHD 0.436409
BIF 3449.897476
BMD 1.157608
BND 1.489433
BOB 7.999802
BRL 6.467445
BSD 1.157703
BTN 99.624818
BWP 15.639883
BYN 3.788632
BYR 22689.120169
BZD 2.325498
CAD 1.593419
CDF 3340.857025
CHF 0.932077
CLF 0.029189
CLP 1120.124581
CNY 8.31046
CNH 8.319742
COP 4647.912571
CRC 584.147446
CUC 1.157608
CUP 30.676617
CVE 110.17869
CZK 24.634826
DJF 206.161172
DKK 7.462741
DOP 69.645442
DZD 150.959052
EGP 57.198232
ERN 17.364123
ETB 160.673822
FJD 2.621461
FKP 0.862211
GBP 0.864374
GEL 3.137261
GGP 0.862211
GHS 12.06865
GIP 0.862211
GMD 82.773031
GNF 10046.130227
GTQ 8.883041
GYD 242.113474
HKD 9.085945
HNL 30.298265
HRK 7.535721
HTG 152.000928
HUF 399.166648
IDR 18927.125132
ILS 3.889239
IMP 0.862211
INR 99.665086
IQD 1516.611941
IRR 48764.243764
ISK 141.745126
JEP 0.862211
JMD 185.594612
JOD 0.820722
JPY 172.244571
KES 149.560939
KGS 101.232549
KHR 4640.404962
KMF 489.957525
KPW 1041.811554
KRW 1614.365421
KWD 0.35395
KYD 0.964753
KZT 618.290994
LAK 24965.658478
LBP 103730.237582
LKR 348.896687
LRD 232.120171
LSL 20.729361
LTL 3.418116
LVL 0.700225
LYD 6.296068
MAD 10.492281
MDL 19.680753
MGA 5175.990031
MKD 61.511814
MMK 2429.790684
MNT 4151.491855
MOP 9.359789
MRU 46.052924
MUR 52.925977
MVR 17.823837
MWK 2007.453446
MXN 21.786903
MYR 4.915783
MZN 74.040021
NAD 20.729361
NGN 1770.897275
NIO 42.606624
NOK 11.96498
NPR 159.398133
NZD 1.958748
OMR 0.445099
PAB 1.157703
PEN 4.106883
PGK 4.86419
PHP 66.29271
PKR 329.826726
PLN 4.255115
PYG 8960.980294
QAR 4.221093
RON 5.073461
RSD 117.152283
RUB 90.584435
RWF 1663.711081
SAR 4.341987
SBD 9.614792
SCR 16.99834
SDG 695.143539
SEK 11.311331
SGD 1.490033
SHP 0.909698
SLE 26.219151
SLL 24274.469129
SOS 661.587452
SRD 42.974466
STD 23960.151957
SVC 10.130064
SYP 15051.044508
SZL 20.725764
THB 37.673188
TJS 11.067673
TMT 4.063205
TND 3.409829
TOP 2.711237
TRY 46.63318
TTD 7.858912
TWD 34.082264
TZS 3021.357697
UAH 48.467432
UGX 4147.750803
USD 1.157608
UYU 46.833312
UZS 14793.41138
VES 135.399584
VND 30283.029777
VUV 138.491433
WST 3.195153
XAF 655.449207
XAG 0.030553
XAU 0.000348
XCD 3.128494
XDR 0.812399
XOF 655.443549
XPF 119.331742
YER 279.389174
ZAR 20.726515
ZMK 10419.865027
ZMW 27.061035
ZWL 372.749359
  • CMSC

    0.0900

    22.314

    +0.4%

  • CMSD

    0.0250

    22.285

    +0.11%

  • RBGPF

    0.0000

    69.04

    0%

  • SCS

    0.0400

    10.74

    +0.37%

  • RELX

    0.0300

    53

    +0.06%

  • RIO

    -0.1400

    59.33

    -0.24%

  • GSK

    0.1300

    41.45

    +0.31%

  • NGG

    0.2700

    71.48

    +0.38%

  • BP

    0.1750

    30.4

    +0.58%

  • BTI

    0.7150

    48.215

    +1.48%

  • BCC

    0.7900

    91.02

    +0.87%

  • JRI

    0.0200

    13.13

    +0.15%

  • VOD

    0.0100

    9.85

    +0.1%

  • BCE

    -0.0600

    22.445

    -0.27%

  • RYCEF

    0.1000

    12

    +0.83%

  • AZN

    -0.1200

    73.71

    -0.16%

Pfizer sees Covid-19 drug sales topping $50 bn in 2022
Pfizer sees Covid-19 drug sales topping $50 bn in 2022

Pfizer sees Covid-19 drug sales topping $50 bn in 2022

Pfizer forecast more than $50 billion in 2022 sales for its Covid-19 vaccine and therapeutic on Tuesday as the pharmaceutical giant reported a more than doubling of annual profits on strong sales of its innoculation.

Text size:

Pfizer, whose vaccinee developed with German company BioNTech was the first approved to counter the deadly virus, sees slightly lower 2022 revenues for the vaccine compared with the just-finished year, but a big infusion of revenues from Paxlovid, the company's pill for Covid-19.

Chief Executive Albert Bourla described 2021 as a "watershed year" for Pfizer, adding that the company's efforts in the pandemic "have fundamentally changed our company forever."

Still, shares fell Tuesday following the results, which lagged estimates in terms of fourth-quarter revenues.

Besides vaccines, sales were mixed across Pfizer's other divisions. Revenues dipped for internal medicine and inflammation and immunology, but rose for oncology, hospitals and rare disease.

Analysts have also projected higher 2022 profits compared with the company's forecasts.

- Heavy interest in therapeutic -

Pfizer reported annual profits of $22 billion, more than double the 2020 level. Annual revenues nearly doubled to $81.3 billion, with $36.8 billion from the Covid-19 vaccine.

The company projected 2022 revenues of between $98 and $102 billion.

The results are the latest to show how the coronavirus has transformed Pfizer, which a year ago had projected just $15 billion in Covid-19 vaccines sales in 2021 and ended up selling more than twice that amount after repeatedly lifting the forecast.

For 2022, Pfizer expects $32 billion in revenue from Covid-19 vaccines and $22 billion in revenues from Paxlovid.

Bourla said the company is currently working on a new vaccine candidate based on the Omicron variant of Covid-19, as well as a new "potential next-generation oral Covid-19 treatment."

The company expects to produce 120 million treatment courses for Paxlovid, with six million in the first quarter and 30 million the first half of 2022.

Pfizer executives described heavy interest in Paxlovid, with ongoing contract talks with about 100 governments around the world. The treatment has so far been approved in about 40 countries.

Bourla said the sales for Paxlovid "could be way bigger" than current forecasts. The 2022 estimate of $22 billion is based on signed contracts and negotiations where there is essentially an agreement, he said.

However, Chief Financial Officer Frank D'Amelio cautioned that there was "less potential upside" to 2022 estimates for Covid-19 vaccine revenues, compared with 2021 "when the vaccine was newly available and few people had received any doses of the vaccine."

Pfizer's scientists "continue to monitor the Covid-19 virus and believe it is unlikely that it will be fully eradicated in the foreseeable future," Bourla said.

"That said, we now have the tools -- in the forms of vaccines and treatments -- that we believe will help enable us to not only better manage the pandemic but also help countries move into the endemic phase," Bourla said.

"In other words, we believe these tools will help allow us to go back to normality and spend time with family and friends, travel, attend indoor dining and concerts, and enjoy many other activities while lowering the risk of overburdening hospitals and healthcare systems around the world."

Shares fell 2.8 percent to $51.75 in midday trading.

A.Stransky--TPP